

**REMARKS**

Applicants request entry of the Preliminary Amendment before examination on the merits.

Support for the amendments are found throughout the specification. For example, support for amended claims 1, 5, 10 and 15 is provided in claim 4, and at page 3, lines 13-15, and page 14, lines 8-11, which describes that enzyme is secreted at levels of 1 picogram/cell/day and at least 70% of said enzyme binds the mannose -6-phosphate receptor. Support for amendment to claim 3 is found in claim 2. Support for amendment to claim 6 is found in claim 10. Support for amendment to claim 16 is found at page 5, line 28, which describes treatment of CLN2 Batten disease. Support for new claims 18-19 is provided, for example, in claims 2 and 16 and on page 5, line 26, to page 6, line 23 and page 37, line 20, which describes enzymes capable of being produced by the method and disease treatable by said enzymes. Support for new claims 20-25 for CLN2 Batten disease/tripeptidyl peptidase I (TPP I) is provided, for example, in claims 2 and 16, at page 5, line 28, to page 6, lines 2 and at page 38, line 6. Support for new claims 26-30 for Mucopolysaccharidosis Type IVa/galactose-6-sulfatase (G6S) is provided, for example, in claims 2 and 16 and on page 5, line 24, page 6, line 20, and on page 37, line 3.

Applicants submit the application is in condition for allowance and request notice of the same.

Dated: March 5, 2009

Respectfully submitted,

By Katherine L. Neville  
Katherine L. Neville

Registration No.: 53,379  
MARSHALL, GERSTEIN & BORUN LLP  
233 S. Wacker Drive, Suite 6300  
Sears Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300  
Attorney for Applicant